Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/Simvastatin vs Rosuvastatin or Doubling Statin Dose in CVD and Diabetes
NCT00862251Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Apr 2009
- Primary completion
- Mar 2011
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ezetimibe in hypercholesterolemia (3 arms), sponsored by Organon & Co. Primary endpoint: Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin at 6 weeks. Started Apr 2009; status: completed.
02
Drugs
ezetimibe
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT00862251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00862251.